Dance/Movement Therapy for Bone Mineral Density in Schizophrenia

Sponsor
Beijing HuiLongGuan Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05716802
Collaborator
(none)
60
1
2
24.1
2.5

Study Details

Study Description

Brief Summary

Fractures are common accidents for long-term hospitalized patients with schizophrenia (SZ) in psychiatric hospitals, and once they occur, patients usually endure the pain of fractures for a long time. Accumulating evidence has supported implementing dance/movement therapy (DMT) as a promising intervention for patients with SZ. However, no study has been conducted to investigate its role in balance ability and metabolic parameters in SZ. This study was designed to investigate the treatment outcome of a 12-week DMT intervention on bone mineral density, balance ability, and metabolic profile in patients with SZ using a randomized, controlled trial design.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: dance/movement therapy
  • Behavioral: treatment as usual
N/A

Detailed Description

Schizophrenia (SZ) is a chronic, severe psychiatric disorder that affects approximately 1% of the population (Barnett 2018). The psychiatric symptoms and high rate of relapse of SZ can significantly impair cognitive and social functioning, including problem-solving skills, interpersonal relationships, and work performance (Brekke et al., 2005). Moreover, individuals with SZ usually have higher disability and premature mortality rates compared to the general population (McCutcheon et al., 2020). Falls are a common concern in hospital settings, with studies reporting a fall rate between three and five falls per 1000 bed days (Healey et al., 2008; Oliver et al., 2010; Pham et al., 2022).Osteoporosis and its precursors, e.g. osteopenia and low bone mineral density (BMD), have been reported in chronic patients with SZ (Kishimoto et al., 2012; Stubbs et al., 2014; Gomez et al., 2016; Cui et al., 2018) and were strong predictors for subsequent falls and fractures in psychiatric hospitals (Stubbs et al. 2015; Stubbs et al., 2018).

Dance/movement therapy (DMT), as one of the creative arts therapies (Millard et al., 2021), is an emerging therapy for the rehabilitation of patients with SZ in recent years (Xia and Grant 2009; Ren and Xia 2013; Millman et al., 2021; Wu et al., 2022). DMT therapy uses dance activities and body movements to enhance well-being, mood, and quality of life. DMT therapy uses movement, dance, and interpersonal communication to explore a person's emotional, cognitive, social, and physical integration, enabling patients to enhance self-expression, accept and reconnect with their bodies, and strengthen their fitness (de Witte et al., 2021). The patients share their emotions, concerns, and coping strategies with others through dance/movement (Biondo et al., 2021; Bryl et al., 2022). It can be applied to individuals of all ages, races, and genders and can be efficacious in individuals who experience losses in social, physical, and psychological functions. DMT has also been used to improve the cognition and social function of patients with mental diseases in psychiatric hospitals (Millman et al. 2021). In particular, a few studies have reported a critical role of DMT intervention in negative symptoms in chronic patients with SZ (Röhricht and Priebe 2006; Priebe et al., 2016). However, there is still a lack of evidence that whether DMT is an effective therapy to increase the mean bone mineral density and reduce the risk of fractures due to falls in long-term hospitalized patients with SZ.

In the present study, we hypothesized that DMT intervention was effective to increase BMD and balance ability and decrease the metabolic parameters in long-term hospitalized male veterans with SZ as compared to the control group. We also examined whether DMT intervention can significantly change BMI, the levels of lipid profile, and serum calcium in patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Dance/Movement Therapy for Improving Bone Mineral Density in Long-term Patients With Schizophrenia: a Randomized Controlled Trial
Actual Study Start Date :
Jul 7, 2020
Actual Primary Completion Date :
Jan 12, 2022
Actual Study Completion Date :
Jul 12, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: dance/movement therapy (DMT), twice a week, 12 weeks,

The multiple-session DMT intervention was applied to participants twice a week as a total of 24 sessions of 60 minutes over three months. The DMT intervention protocol was developed based on the therapist's experience, the theoretical frameworks, and the DMT approach described in a previous study (Bryl and Goodill 2019).

Behavioral: dance/movement therapy
dance/movement therapy plus treat as usual

Placebo Comparator: Treatment as usual (TAU), twice a week, 12 weeks,

The TAU group sessions were conducted by the licensed professional employed at the hospital. The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).

Behavioral: treatment as usual
The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).

Outcome Measures

Primary Outcome Measures

  1. Bone mineral density measurement [week 12]

    The primary outcome measure was the BMD of patients recruited, which was assayed by an Erik AKDX-09W-1 bone density device (Shenzhen Ekere Electric Co.). The test was performed using the dual-energy X-ray absorptiometry method. Measurements were done at the distal end of the flexor bone of the patient's left forearm for fan beam and line scan, which were reviewed by an experienced radiologist who was blinded to the clinical and pharmacological characteristics and randomization of the patients.

Secondary Outcome Measures

  1. panss [week 12]

    THE POSITIVE AND NEGATIVE SYNDROME SCALES

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 60 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No

Inclusion Criteria: 1) a diagnosis of SZ using the DSM-V; 2) male veterans, aged 40 to 60 years with a disease duration of 5 years or more and a long-term hospitalization of 3 years or more; 3) ability to understand Mandarin Chinese; 4) legally eligible to sign an informed consent form; 5) current antipsychotic medication stability for more than 2 years; 6) reduced bone mass, osteoporosis, and severe osteopenia after bone density analysis; 7) no comorbid serious physical illness and physical impairments and can cooperate with nurses to complete the general intensity of activity training and 8) consent for pre- and post-session interviews.

Exclusion Criteria:1) substance dependence or abuse; 2) hypercalcemia and hyperuricemia; 3) history of kidney stones or renal calculi; and 4) lower limb injury and motor dysfunction, and inability to complete DMT intervention for various reasons.

-

Contacts and Locations

Locations

Site City State Country Postal Code
1 DMT Baoding Hebei China 050899

Sponsors and Collaborators

  • Beijing HuiLongGuan Hospital

Investigators

  • Study Director: Hengyong Guan, Dr., hebei province veterans hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Haixia Liu, Dr., Beijing HuiLongGuan Hospital
ClinicalTrials.gov Identifier:
NCT05716802
Other Study ID Numbers:
  • xmh123
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2023